NCT00835926View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

PHASE4CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

September 30, 2003

Study Completion Date

September 30, 2003

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza virus vaccine

0.5 mL, Intramuscular

BIOLOGICAL

Influenza virus vaccine

0.5 mL, Intramuscular

Trial Locations (1)

23507

Norfolk

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00835926 - A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination | Biotech Hunter | Biotech Hunter